Ibustrin

Indobufen, the active ingredient in Ibustrin, is a platelet aggregation inhibitor presented as an oral tablet for oral use. It helps prevent arterial thrombosis and is employed in the secondary prevention of cardiovascular events such as myocardial infarction and ischemic stroke.

GNH USA supplies Ibustrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibustrin, an antiplatelet agent, is used in conditions where platelet‑driven clot formation is a major risk.

- Prevention of arterial thrombosis: reduces the formation of occlusive clots in arteries. - Secondary prevention of myocardial infarction: lowers the chance of a recurrent heart attack. - Secondary prevention of ischemic stroke: decreases the risk of another stroke caused by arterial blockage.

Common Side Effects: - Nausea: mild stomach upset may occur. - Dyspepsia: indigestion or upper abdominal discomfort. - Headache: transient head pain reported by some patients. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Severe bleeding: unexpected or prolonged hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should consider several safety measures. - Bleeding risk assessment: evaluate patient history for prior hemorrhage. - Liver function monitoring: check hepatic enzymes periodically. - Concomitant anticoagulant review: avoid combining with other strong anticoagulants unless necessary. - Renal impairment caution: adjust use in patients with reduced kidney function. - Hypersensitivity avoidance: discontinue if allergic reactions develop. - Store at ambient temperature: keep in the original pack, protect from moisture.

Indobufen may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect and bleeding risk. - Other antiplatelet agents (e.g., clopidogrel): additive platelet inhibition. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding. - Direct oral anticoagulants (DOACs): potential for excessive anticoagulation.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible enhancement of hypotensive effects. - Diuretics: monitor blood pressure and electrolyte balance. - Antihypertensive agents: observe for additive blood‑pressure lowering.